Company

Sirius Therapeutics

Sirius Therapeutics develops nucleic acid therapies for cardiovascular diseases.

About

Founded in 2022 and based in Shanghai, China, Sirius Therapeutics develops nucleic acid therapies for cardiovascular diseases. Its pipeline includes SRSD107 injection, SRSD101, and SRSD216, with a technology platform for small nucleic acid drug development. In May 2025, it raised approximately USD 50 million in Series B2 funding, with BioTrack Capital, OrbiMed Advisors, Creacion Ventures, and Hankang Capital participating.

3Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in